Keryx Biopharmaceuticals (KERX) Posts Earnings Results, Misses Expectations By $0.08 EPS

Keryx Biopharmaceuticals (NASDAQ:KERX) posted its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.18) by ($0.08), Bloomberg Earnings reports. Keryx Biopharmaceuticals had a negative return on equity of 10,954.62% and a negative net margin of 323.92%. The firm had revenue of $18.70 million for the quarter, compared to analysts’ expectations of $17.53 million. During the same period last year, the business earned ($0.32) earnings per share. The firm’s revenue for the quarter was up 96.8% on a year-over-year basis.

Keryx Biopharmaceuticals (KERX) traded down $0.34 on Wednesday, reaching $4.29. The company’s stock had a trading volume of 1,548,312 shares, compared to its average volume of 1,178,335. The firm has a market cap of $535.31, a price-to-earnings ratio of -3.08 and a beta of 2.71. The company has a debt-to-equity ratio of 13.95, a current ratio of 4.46 and a quick ratio of 3.76. Keryx Biopharmaceuticals has a 12-month low of $4.01 and a 12-month high of $8.38.

In other Keryx Biopharmaceuticals news, COO Christine A. Carberry sold 9,048 shares of the firm’s stock in a transaction that occurred on Thursday, January 18th. The stock was sold at an average price of $4.87, for a total value of $44,063.76. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders sold a total of 16,561 shares of company stock worth $80,128 in the last ninety days. Insiders own 2.58% of the company’s stock.

KERX has been the subject of a number of recent research reports. Zacks Investment Research raised Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, October 16th. ValuEngine lowered Keryx Biopharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, November 10th. Finally, Stifel Nicolaus lowered their price objective on Keryx Biopharmaceuticals from $7.00 to $5.00 and set a “hold” rating on the stock in a report on Wednesday, November 8th. One analyst has rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the company’s stock. Keryx Biopharmaceuticals currently has an average rating of “Hold” and a consensus target price of $7.44.

TRADEMARK VIOLATION WARNING: “Keryx Biopharmaceuticals (KERX) Posts Earnings Results, Misses Expectations By $0.08 EPS” was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international trademark and copyright legislation. The legal version of this article can be read at

About Keryx Biopharmaceuticals

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Earnings History for Keryx Biopharmaceuticals (NASDAQ:KERX)

Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply